Reduction of the serotonin 5-HT1B and 5-HT2A receptor-mediated contraction of human pulmonary artery by the combined 5-HT1B receptor antagonist and serotonin transporter inhibitor LY393558

Baranowska-Kuczko, Marta and Kozłowska, Hanna and Schlicker, Eberhard and Göthert, Manfred and MacLean, Margaret R. and Kozłowski, Mirosław and Kloza, Monika and Sadowska, Olga and Malinowska, Barbara (2020) Reduction of the serotonin 5-HT1B and 5-HT2A receptor-mediated contraction of human pulmonary artery by the combined 5-HT1B receptor antagonist and serotonin transporter inhibitor LY393558. Pharmacological Reports, 72 (3). pp. 756-762. ISSN 1734-1140

[thumbnail of Baranowska-Kuczko-etal-PR-2020-Reduction-of-the-serotonin-5-HT1B-and-5-HT2A-receptor-mediated-contraction]
Preview
Text (Baranowska-Kuczko-etal-PR-2020-Reduction-of-the-serotonin-5-HT1B-and-5-HT2A-receptor-mediated-contraction)
Baranowska_Kuczko_etal_PR_2020_Reduction_of_the_serotonin_5_HT1B_and_5_HT2A_receptor_mediated_contraction.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (621kB)| Preview

    Abstract

    Background: LY393558 is a combined antagonist of serotonin (5-HT) 5-HT 1B receptors and inhibitor of serotonin transporter (SERT). LY393558 reduces 5-HT-induced vasoconstriction and remodelling of rat and/or mouse pulmonary arteries. The aim of our study was to examine the effect of LY393558 on the 5-HT-stimulated vasoconstriction of human pulmonary arteries (hPAs) and to determine the underlying mechanism(s). Methods: Vascular effects of 5-HT receptor agonists, antagonists and a SERT inhibitor were examined in organ bath studies on intralobar hPAs obtained from patients during resection of lung carcinoma. Results: Serotonin and agonists of the 5-HT 1B receptor (5-carboxamidotryptamine, 5-CT) and 5-HT 2A receptor (α-methyl-5-HT) contracted endothelium-intact hPAs in a concentration-dependent fashion. The 5-HT 1B antagonists SB224289 and GR55562 reduced responses induced by 5-HT and 5-CT and the 5-HT 2A antagonist ketanserin inhibited the effects of 5-HT and α-methyl-5-HT. Administration of the SERT inhibitor citalopram (at a concentration that failed to modify the 5-HT-induced vasoconstriction) in combination with SB224289 or GR55562 was more effective in inhibiting the response to 5-HT than the 5-HT 1B antagonists alone. LY393558 showed the greatest antagonistic effect against the vasoconstriction elicited by 5-HT, 5-CT and α-methyl-5-HT. Conclusions: LY393558 reduces the 5-HT-induced contraction antagonizing 5-HT 1B and 5-HT 2A receptors probably due to synergic interaction between SERT inhibition and 5-HT 1B receptor antagonism. Thus, it might represent a valuable future option in the pulmonary arterial hypertension therapy.